| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Michael Berelowitz last filed a Form 4 in December 2015, as Director at ORMP. Michael Berelowitz's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 22,896 shares of ORMP. The ORMP filings lean toward selling, a net 2,000 shares.
Michael Berelowitz has 3 Form 4 filings on record from February 2015 to December 2015, all as Director at Oramed Pharmaceuticals (ORMP), 2015.
The 4 reported transactions were 3 open-market sales and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $18K.
The largest open-market sale was 1,300 shares of ORMP at an average $8.70 on December 8, 2015, about $11K.
Shares as reported in the last Form 4 for each company; the most recent is from December 2015. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.